Steroid hormone receptors and hormonal therapies in human breast cancer

Journal of Experimental and Clinical Cancer Research

Volumn 15, Issue 1, 1996, Pages 23-32

  Gorlich M ^a   Jandrig, B ^a  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Aromatase inhibitors; Estrogen receptor; Hormonal therapy; Medroxyprogesterone acetate; Progesterone receptor; Tamoxifen

Indexed keywords

AROMATASE INHIBITOR; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

BREAST CANCER; FEMALE; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0029877822     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Crawford D.J., Cowan S., Fitch R., Smith D.C., Leake R.E.: Stability of oestrogen receptor status in sequential biopsies from patients with breast cancer Br. J. Cancer 56: 137-140, 1987.
2. Hawkins R.A., Tesdale A.L., Anderson E.D.C., Levack P.A., Chetty U., Forrest A.P.M.: Does the oestrogen receptor concentration of a breast cancer change during systemic therapy? Br. J. Cancer 61: 877-880, 1990.
3. Encarnacion C.A., Ciocca D.R., McGuire W.L., Clark G.M., Fuqua A.W., Osborne C.K.: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res. Treatm. 26: 237-246, 1993.
4. Bojar H. Receptors and Cancer. Tumor Biol. 8: 120-129, 1987.
5. Noguchi S., Miyauchi K., Nishizawa Y., Koyama H.: Induction of progesterone receptor with tamoxifen in human breast cancer with special reference to its behaviour over time. Cancer 61: 1345-1349, 1988.
6. Melchor J.C., Rodriguez-Escudero F.J., Luján S., Corcöstegui B.: Variation of estrogen and progesterone receptor status in breast cancer after tamoxifen therapy. Oncology 47: 467-470, 1990.
7. Lundgren S., Soreide J.A., Lea O.A.: Influence of tamoxifen on the tumor content of steroid hormone receptors (ER, PR, and AR) in patients with primary breast cancer. Anticancer Res. 14: 1313-1316, 1994.
8. Murray P.A., Gomm J., Ricketts D., Powles T., Coombes R.C.: The effect of endocrine therapy on the levels of oestrogen and progesteron receptor and transforming growth factor-β1 in metastatic human breast cancer: An immunocytochemical study. Eur. J. Cancer 30A: 1218-1222, 1994.
9. Noguchi S., Motomura K., Inaji H., Imaoka S., Koyama H.: Up-regulation of estrogen receptors by tamoxifen in human breast cancer. Cancer 71: 1266-1272, 1993.
10. Kiang D.T., Kollander R.E., Thomas T., Kennedy B.J.: Up-regulation of estrogen receptors by nonsteroidal anti-estrogens in human breast cancer.Cancer Res. 49: 5312-5316, 1989.
11. Sunderland M.C., Osborne C.K.: Tamoxifen in premenopausal patients with metastatic breast cancer: A review. J. Clin. Oncol. 9: 1283-1297, 1991.
12. Rose D.P., Chlebowski R.T., Connolly M., Jones L.A., Wynder E.L.: Effects of tamoxifen adjuvant therapy and a low-fat diet on serum binding proteins and estradiol bioavailability in postmenopausal breast cancer patients. Cancer Res. 52: 5386-5390, 1992.
13. Iino Y., Wolf D.M., Langan-Fahey S.M. et al.: Reversible control of oestradiol-stimulated growth of MCF-7 tumours by tamoxifen in the athymic mouse. Br. J. Cancer 64: 1019-1024, 1991.
14. Daffada A.A.I., Johnston S.R.D., Smith I.E., Detre S., King N., Dowsett M.: Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer. Cancer Res. 55: 288-293, 1995.
15. Castles C.G., Klotz D.M., Fuqua S.A.W., Hill S.M.: Coexpression of wild-type and variant oestrogen receptor mRNAs in a panel of human breast cancer cell lines. Br. J. Cancer 71: 974-980, 1995.
16. Murphy L.C., Hilsenbeck S.G., Dotzlaw H., Fuqua S.A.W.: Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin. Cancer Res. 1: 155-159, 1995.
17. R-1 compared to the parental MCF-7 cell line. Mol. Cell. Endocr. 109: 197-207, 1995.
18. Roodi N., Bailey L.R., Kao W.J., Verrirer C.S., Yee C.J., Dupont W.D., Parl F.F.: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. J. Natl. Cancer Inst. 87: 446-451, 1995.
19. Catherino W.H., Jordan V.C.: The biological action of cDNAs from mutated estrogen receptors transfected into breast cancer cells. Cancer Lett. 90: 35-42, 1995.
20. Catherino W.H., Jordan V.C.: Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamofixen analogue. Cancer Lett. 92: 39-47, 1995.
21. Horwitz K.B.: Hormone "resistance" in breast cancer: The role of normal and mutant steroid receptor. In: Dickson R., Lippman M., eds.: Mammary tumorigenesis and malignant progression. Kluwer Academic Publishers 111-127, 1994.
22. Wolf D.M., Jordan V.C.: The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treatm. 31: 129-138, 1994.
23. Wolf D.M., Langan-Fahey S.M., Parker C.J., McCague R., Jordan V.C.: Investigation of the mechanism of tamoxifen-stimulated breast tumor growth nonisomerable analogues of tamoxifen and metabolites. J. Natl. Cancer Inst. 85: 806-812, 1993.
24. Fendl K.C., Zimniski S.J.: Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res. 52: 235-237, 1992.
25. Fentiman I.S.: The role of tamoxifen in the prevention of breast cancer. Eur. J. Cancer 26: 655-656, 1990.
26. Dietel M., Löser R., Röhlke P. et al.: Effect of continuous vs intermittent application of 3-OH-tamoxifen on the proliferation of the human breast cancer cell line MCF-7 M1. J. Cancer Res. Clin. Oncol. 115: 36-40, 1989.
27. Thompson E.W., Reich R., Shima T.B. et al.: Differential regulation of growth and invasiveness of MCF-7 breast cancer cells by antiestrogens. Cancer Res. 48: 6764-6768, 1988.
28. Bracke M.E., Van Larebeke N.A., Vyncke B.M., Marcel M.M.: Retinoic acid modulates both invasion and plasma membrane ruffling of MCF-7 human mammary carcinoma cells in vitro. Br. J. Cancer 63: 867-872, 1991.
29. Millon R., Nicora F., Muller D., Eber M., Klein-Soyer L.C., Abecassis J.: Modulation of human breast cancer cell adhesion by estrogens and antiestrogens. Clin. Exp. Metastasis 7: 405-415, 1989.
30. Dickson R.B., Thompson E.W., Lippman M.E.: Regulation of proliferation, invasion and growth factor synthesis in breast cancer by steroids. J. Steroid Biochem. Molec. Biol. 37: 305-316, 1990.
31. Bracke M.W., Charlier C., Bruyneel E.A., Labit C., Mareel M.M., Castronovo V.: Tamoxifen restores the E-cadherin function in human breast cancer MCF7/6 cells and suppresses their invasive phenotype. Cancer Res. 54: 4607-4609, 1994.
32. Coradini D., Biffi A., Cappelletti V., di Fronzo G.: Activity of tamoxifen and new antiestrogens on estrogen receptor positive and negative cells. Anticancer Res.: 14: 1059-1064, 1994.
33. Santen R.J.: The principles of aromatase inhibition in the treatment of breast cancer. In: Jonat W., Santen R.J. eds.: Aromatase inhibition: Present and future. Carnforth: The Partenon Publ. Group 11-27, 1991.
34. Miller W.R.: The clinical relevance of aromatase activity in breast tumor tissue. In: Jonat W., Santen R.J. eds.: Aromatase inhibition: Present and future. Carnforth: The Parthenon Publ. Group 37-45, 1991.
35. Petru E., Schmähl D.: On the role of additive hormone mono-therapy with tamoxifen, medroxyprogesterone acetate and aminoglutethimide, in advanced breast cancer. Klin. Wschr. 65: 959-966, 1987.
36. Höffken K., Jonat W., Possinger K.: Clinical experience with 4-hydroxy-androstenedione in the treatment of advanced breast cancer. In: Jonat W., Santen R.J. eds.: Aromatase inhibition. Present and future. Carnforth: The Partenon Publ. Group 65-76, 1991.
37. Evans T.R.J., Rowlands M.G., Silva M.C., Law M., Coombes R.C.: Prognostic significance of aromatase and estrone sulfatase enzymes in human breast cancer. J. Steroid Biochem. Molec. Biol. 44: 583-587, 1993.
38. Bezwoda W.R., Mansor R., Dansey R.: Correlation of breast tumor aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 44: 345-349, 1987.
39. Noguchi T., Kitawaki J., Tamura T. et al.: Relationship between aromatase activity and steroid receptor levels in ovarian tumors from postmenopausal women. J. Steroid Biochem. Molec. Biol. 44: 657-660, 1993.
40. Zhou J.L., Brodie A.: The effect of aromatase inhibitor 4-hydroxy-androstenedione on steroid receptors in hormone-dependent tissues of the rat. J. Steroid Biochem. Molec. Biol. 52: 71-76, 1995.
41. Yue W., Savinov A., Wang J., Brodie A.: Inhibition of mammary tumor growth in nude mice treated with aromatase inhibitors. Proc. Amer. Assoc. Cancer Res. 36: 253, 1995.
42. Parazzini F., Colli E., Scatigna M., Tozzi L.: Treatment with tamoxifen and progestins for metastatic breast cancer in postmenopausal women: A quantitative review of published randomized clinical trials. Oncology 50: 483-489, 1993.
43. Muss H.B., Case L.D., Atkins J.N. et al.: Tamoxifen versus high-dose oral medroxyprogesterone acetate as initial endocrine therapy for patients with metastatic breast cancer: A Piedmont Oncology Association study. J. Clin. Oncol. 12: 1630-1638, 1994.
44. Noguchi S., Yamamoto H., Inaji H., Imaoka S., Koyama H.: Inability of medroxyprogesterone acetate to down regulate estrogen receptor level in human breast cancer. Cancer 65: 1375-1379, 1990.
45. Pollow K., Kreinberg R., Juchem M., Hoffmann G.: High-dose medroxyprogesterone acetate (MPA) therapy in progressive mammary cancer patients under special consideration of MPA serum levels. Tumor Diagn. Ther. 14: 49-55, 1993.
46. Nomura Y., Tashiro H., Hisamatsu K., Shinozuka K.: Steroid hormone receptors and response to high-dose medroxyprogesterone acetate in advanced breast cancer. Anticancer Res. 8: 647-652, 1988.
47. Braunsberg H.A., Codhman N.G., Wong W.: Hormonal therapies for breast cancer: Can progestogens stimulate growth? Cancer Lett. 30: 213-216, 1986.
48. Classen S., Possinger K., Pelka-Fleischer R., Wilmanns W.: Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells. J. Steroid Biochem. Molec. Biol. 45: 315-319, 1993.
49. Bonomi P., Johnson P., Anderson K. et al.: Primary hormonal therapy of advanced breast cancer with megestrol acetate: Predictive value of estrogen receptor and progesterone receptor levels. Sem. Oncol. 12, Suppl. 1: 48-54, 1985.
50. Brufmen G., Iverson R., Heim N., Gez E., Sulkes A.: Megestrol acetate in advanced breast carcinoma after failure to tamoxifen and/or aminoglutethimide. Oncology 51: 258-261, 1994.
51. Ettinger D.S., Allegra J., Bertino J.R. et al.: Megestrol acetate vs tamoxifen in advanced breast cancer: Correlation of hormone receptors and response. Sem. Oncol. 13, Suppl. 4: 9-14, 1986.
52. Gundersen S., Kvinnsland S., Klepp O., Lund E., Hannisdal E., Host H., for the Norwegian Breast Cancer Group: Chemotherapy with and without high-dose medroxyprogesterone acetate in oestrogen-receptor negative advanced breast cancer. Eur. J. Cancer 28: 390-394, 1992.
53. Shaikh N.A., Owen A.M., Gilchik M.W., Braunsberg H.: Actions of medroxyprogesterone acetate on the efficacy of cytotoxic drugs: Studies with human breast cancer cells in culture. Int. J. Cancer 43: 458-463, 1989.
54. Mansour E.G., Ravdin P.M., Dressler L.: Prognostic factors in early breast cancer. Cancer 74: 381-400, 1994.
55. Gion M., Mione R., Pappagallo G., Gatti C., Nascimben O., Sampognaro E., Meo S.: Biochemical parameters for prognostic evaluation in patients with breast cancer. Anticancer Res. 14: 693-698, 1994.
56. Vizcarra E., Lluch A., Cibrian R., Jarque F., Garcia-Conde J. CA 15.3, CEA and TPA tumor markers in the early diagnosis of breast cancer relapse. Oncology 51: 491-496, 1994.
57. Rochefort H.: Cathepsin D in breast cancer: A tissue marker associated with metastasis. Eur. J. Cancer 28A: 1780-1783, 1992.
58. Horwitz K.B.: Editorial: When tamoxifen turns bad. Endocrinology 136: 821-823, 1995.
59. Frigo B., Pilotti S., Zurrida S., Ermellino L., Manzari A., Rilke F.: Analysis of estrogen and progesterone receptors on preoperative fine needle aspirates. Breast Cancer Res. Treatm. 33: 179-184, 1995.
60. Petrangeli E., Lubrano C., Ortolani F., Ravenna L., Vacca A., Sciacchitano S., Frati L., Gulino A.: Estrogen receptors: New perspectives in breast cancer management. J. Steroid Biochem. Molec. Biol. 49: 327-331, 1994.